For the year ending 2025-12-31, DFTX had -$15,904K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Total | 117,665 |
| Total | 48,644 |
| Loss from operations | -166,309 |
| Total other expense, net | -17,484 |
| Net loss | -183,793 |
| Stock-based compensation | 20,096 |
| Change in fair value on directors' deferred share units ('ddsu') | -1,460 |
| Amortization of intangible assets | 0 |
| Change in fair value of 2022 usd financing warrants | 22,831 |
| Gain on extinguishment of contribution payable | 0 |
| Accretion of discounts and premiums on investments, net | 1,821 |
| Unrealized foreign exchange | 0 |
| Other non-cash adjustments | 230 |
| Prepaid and other current assets | -152 |
| Other noncurrent assets | -30 |
| Accounts payable | 3,337 |
| Accrued expenses | 5,958 |
| Other liabilities, long-term | 40 |
| Net cash used in operating activities | -131,560 |
| Purchases of investments | 268,356 |
| Maturity of investments | 116,750 |
| Net cash used in investing activities | -151,606 |
| Proceeds from equity offerings | 258,858 |
| Payment of equity offering costs | 15,946 |
| Proceeds from credit facility | 42,000 |
| Repayment of credit facility | 22,000 |
| Payment of credit facility issuance costs | 447 |
| Proceeds from the 2022 atm net of issuance costs | 0 |
| Payment of deferred financing fees related to 2024 atm | 0 |
| Proceeds from exercise of 2022 usd financing warrants | 3,767 |
| Proceeds from exercise of options | 625 |
| Proceeds from issuance of common shares under espp | 412 |
| Withholding taxes paid on vested rsus | 0 |
| Net cash provided by financing activities | 267,269 |
| Effect of exchange rate changes on cash | -7 |
| Net increase/(decrease) in cash and cash equivalents | -15,904 |
| Cash and cash equivalents, beginning of period | 273,741 |
| Cash and cash equivalents, end of period | 257,837 |
Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics, Inc. (DFTX)